Clinical Trial Update: Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy [Phase 1]

View source ↗

Summary

Phase 1 safety trial of intravenous CCL2-LPM in IgA nephropathy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• CCL2-LPM

Snippet

Sponsor: Osprey Pharmaceuticals USA, Inc. | Conditions: IGA Nephropathy, Proteinuria | Phase 1 | Status: TERMINATED